Outcomes among CBT and BMT/PBSCT recipients. (A) The 1-year and 3-year cumulative incidences of TRM were 8% (95% CI, 3% to 14%) and 9% (95% CI, 3% to 15%) among CBT recipients, respectively, in contrast to 4% (95% CI, 0 to 9%) and 13% (95% CI, 4% to 21%) among BMT/PBSCT recipients, respectively. The differences between the 2 groups were not significant (P = .13). (B) The 3-year cumulative incidences of relapse among recipients were 17% (95% CI, 9% to 25%) after cord blood transplantation and 26% (95% CI, 15% to 37%) after bone marrow transplantation/peripheral blood stem-cell transplantation. The differences between the 2 groups were not significant (P = .34). (C) The 3-year Kaplan-Meier estimate of DFS was 70% (95% CI, 61% to 80%) after cord blood transplantation and 60% (95% CI, 49% to 72%) after bone marrow transplantation/peripheral blood stem-cell transplantation. The differences between the 2 groups were not significant (P = .26). (D) The 3-year Kaplan-Meier estimate of DFS in patients with standard-risk disease was 93% (95% CI, 85% to 100%) after cord blood transplantation and 85% (95% CI, 71% to 99%) after bone marrow transplantation/peripheral blood stem-cell transplantation. The differences between the 2 groups were not significant by nonadjusted comparison (P = .72). The 3-year Kaplan-Meier estimate of DFS in patients with high-risk disease was 56% (95% CI, 42% to 70%) after cord blood transplantation and 45% (95% CI, 30% to 60%) after bone marrow transplantation/peripheral blood stem-cell transplantation. The differences between the 2 groups were not significant by nonadjusted comparison (P = .26).